TP53 and cancer: A compound known as HLI373 (Fig. 1), whose structure differs significantly from active HLI98 compounds, has also been reported to inhibit the E3 ubiquitin ligase activity of HDM2 and thereby selectively to kill cancer cells in a p53-dependent manner.6